TheEdgeResearch
Home / Stocks / SUPN

Supernus, Inc. (SUPN)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$28.61 ▲ +0.92%
Market Cap
$5.94B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.52
52-Wk Range
25.92-43.2
CEO
Jack A. Khattar
Country
US
Currency
USD

Supernus, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Rockville, MD, US. The stock last traded at $28.61, up 0.92% on the session, giving a market capitalisation of $5.94B. On trailing twelve-month figures it carries a trailing P/E of 7.82, a net margin of 32.8%. Its beta of 0.52 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
7.82
Price / Sales
4.33
Price / Book
-56.27
EV / EBITDA
10.81
Gross margin
85.2%
Operating margin
43.7%
Net margin
32.8%
Return on equity
—
Debt / equity
-8.35
Current ratio
0.61
Dividend yield
28.4%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
827
IPO date
2012-04-30
Headquarters
Rockville, MD, US
About Supernus, Inc.

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.

Comparable companies

Supernus, Inc. is most often compared with the following Healthcare names:

ALKSCOLL
More research on SUPN
SUPN technical analysis SUPN TheEdge Score Compare against peers
Open full interactive analysis & DCF →